Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
uniQure ( (QURE) ) has provided an update.
uniQure has reached an agreement with the FDA on critical elements for the Accelerated Approval pathway for AMT-130, a promising gene therapy for Huntington’s disease. The FDA’s acceptance of data from Phase I/II studies, along with the use of cUHDRS as a clinical endpoint, marks a significant milestone towards delivering this potential treatment. The company plans to engage further with the FDA in 2025, aiming to expedite the availability of AMT-130, which has shown promising results in slowing disease progression.
For a thorough assessment of QURE stock, go to TipRanks’ Stock Analysis page.
